Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven ...

Abstract: Mathematics is filled with conjectures that involve infinite recursive structure, representing complex structures and underlying deep relationships. Discovering such conjectures is crucial ...

RXRX remains down by 35% year-to-date and is trading below $5. Thus, the critical question isn’t about a single good ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Fundamental concepts of computers, computation and programming; history and principles of computing; problem solving; input, output; data representation, storage, and file organization; computer ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Three recent graduates from the MSU photo program noticed a glaring gap in the photo-journal world. While there has been ...

Ethereum prioritizes zkEVM security over speed with new 2026 roadmap targeting 128-bit provable security standards.